METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

2001 • 995 citations

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1993 • 837 citations

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

1997 • 828 citations

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

2003 • 803 citations

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 538 citations

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

1993 • 482 citations

Epidermal growth factor receptor tyrosine kinase

1994 • 258 citations

Erlotinib hydrochloride

2005 • 204 citations

Metastatic colorectal cancer

2001 • 130 citations

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man

2004 • 130 citations

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

2003 • 126 citations

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers

2004 • 95 citations

Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)

2003 • 95 citations

Novel therapeutics for head and neck cancer

2002 • 59 citations

Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy

2005 • 52 citations

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection

2004 • 48 citations

Metabolism, Pharmacokinetics, and Excretion of a Highly SelectiveN-Methyl-d-aspartate Receptor Antagonist, Traxoprodil, in Human Cytochrome P450 2D6 Extensive and Poor Metabolizers

2003 • 36 citations

New drugs and combinations in the palliative treatment of colon and rectal cancer

2001 • 13 citations

Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.

1998 • 12 citations

New therapeutic strategies for the treatment and prevention of head and neck cancer

2000 • 10 citations

Cited By (0)

Loading...